RAPT Therapeutics (RAPT) Stock Forecast, Price Target & Predictions
RAPT Stock Forecast
RAPT Therapeutics stock forecast is as follows: an average price target of $42.20 (represents a 2064.10% upside from RAPT’s last price of $1.95) and a rating consensus of 'Hold', based on 7 wall street analysts offering a 1-year stock forecast.
RAPT Price Target
The average price target for RAPT Therapeutics (RAPT) is $42.20 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $27.00. This represents a potential 2064.10% upside from RAPT's last price of $1.95.
RAPT Analyst Ratings
According to 7 Wall Street analysts, RAPT Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for RAPT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (42.86%), 4 'Hold' (57.14%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
RAPT Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 04, 2023 | - | Guggenheim | $55.00 | $19.82 | 177.43% | 2720.51% |
| Jan 04, 2023 | - | Wells Fargo | $48.00 | $19.50 | 146.15% | 2361.54% |
| Dec 08, 2022 | Edward Tenthoff | Piper Sandler | $33.00 | $16.48 | 100.24% | 1592.31% |
| Dec 01, 2022 | - | Goldman Sachs | $27.00 | $17.68 | 52.71% | 1284.62% |
| Nov 11, 2022 | - | Piper Sandler | $34.00 | $21.98 | 54.69% | 1643.59% |
| Sep 21, 2022 | Zegbeh Jallah | Capital One Financial | $48.00 | $24.17 | 98.59% | 2361.54% |
The latest RAPT Therapeutics stock forecast, released on Jan 04, 2023 by Guggenheim company, set a price target of $55.00, which represents a 177.43% increase from the stock price at the time of the forecast ($19.82), and a 2720.51% increase from RAPT last price ($1.95).
RAPT Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.95 | $1.95 | $1.95 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of RAPT Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to RAPT Therapeutics's last price of $1.95. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 11, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 14, 2024 | Wolfe Research | - | Peer Perform | Downgrade |
| May 10, 2024 | Barclays | Overweight | Equal-Weight | Downgrade |
| May 09, 2024 | Guggenheim | Buy | Neutral | Downgrade |
| May 09, 2024 | Guggenheim | Buy | Hold | Downgrade |
| Feb 21, 2024 | Barclays | Overweight | Overweight | Hold |
| Feb 21, 2024 | Cantor Fitzgerald | - | Neutral | Downgrade |
| Feb 21, 2024 | Leerink Partners | - | Market Perform | Downgrade |
| Jan 04, 2023 | Guggenheim | - | Buy | Initialise |
| Jan 04, 2023 | Wells Fargo | Overweight | Overweight | Hold |
RAPT Therapeutics's last stock rating was published by Wells Fargo on Aug 11, 2024. The company gave RAPT a "Overweight" rating, the same as its previous rate.
RAPT Therapeutics Financial Forecast
RAPT Therapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $641.00K | - | $886.00K | $641.00K | $756.00K | $966.00K | $869.00K | $1.22M | $1.30M | $1.53M | $1.28M | $935.00K |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $132.50K | $336.57K | $280.00K | $233.33K | $811.00K | $778.17K | $1.01M | $908.00K | $1.28M | $1.00M | $833.33K | $1.25M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $132.50K | $336.57K | $280.00K | $233.33K | $811.00K | $778.17K | $1.01M | $908.00K | $1.28M | $1.00M | $833.33K | $1.25M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $132.50K | $336.57K | $280.00K | $233.33K | $811.00K | $778.17K | $1.01M | $908.00K | $1.28M | $1.00M | $833.33K | $1.25M |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 4.84% | - | 3.16% | 2.75% | 0.93% | 1.24% | 0.86% | 1.35% | 1.02% | 1.53% | 1.53% | 0.75% |
RAPT Therapeutics's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. RAPT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $641.00K (Dec 22).
RAPT Therapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-24.43M | $-21.42M | $-18.64M | $-20.52M | $-17.70M | $-18.42M | $-15.85M | $-16.23M | $451.26K | $-14.08M | $-11.72M | $-12.70M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $-26.50K | $-16.36M | $-56.00K | $-19.91M | $-162.20K | $-155.63K | $-202.50K | $-15.19M | $-255.28K | $-200.15K | $-166.67K | $-8.86M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $-26.50K | $-13.09M | $-56.00K | $-15.93M | $-162.20K | $-155.63K | $-202.50K | $-12.15M | $-255.28K | $-200.15K | $-166.67K | $-7.09M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $-26.50K | $-19.64M | $-56.00K | $-23.89M | $-162.20K | $-155.63K | $-202.50K | $-18.22M | $-255.28K | $-200.15K | $-166.67K | $-10.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 921.96% | 1.31% | 332.77% | 1.03% | 109.11% | 118.37% | 78.29% | 1.07% | -1.77% | 70.35% | 70.34% | 1.43% |
0 analysts predict RAPT's average Quarter EBITDA for Mar 21 to be $-15.19M, with a high of $-12.15M and a low of $-18.22M. This is -3465.35% lower than RAPT Therapeutics's previous annual EBITDA (Dec 20) of $451.26K.
RAPT Therapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-21.47M | $-20.79M | $-19.46M | $-20.16M | $-17.93M | $-18.65M | $-16.11M | $-16.51M | $-12.73K | $-14.63M | $-12.39M | $-13.14M |
| Avg Forecast | $-21.26M | $-21.41M | $-19.60M | $-19.76M | $-18.21M | $-19.40M | $-20.61M | $-20.31M | $-18.08M | $-21.94M | $-28.00M | $-25.43M | $-16.57M | $-28.73M | $-20.17M | $-25.70M | $-24.20M | $-26.41M | $-15.45M | $-22.54M | $-21.84M | $-22.99M | $-9.17M |
| High Forecast | $-21.26M | $-21.41M | $-19.60M | $-19.76M | $-18.21M | $-19.40M | $-20.61M | $-20.31M | $-18.08M | $-17.63M | $-28.00M | $-25.43M | $-13.25M | $-28.73M | $-16.13M | $-25.70M | $-24.20M | $-26.41M | $-12.36M | $-22.54M | $-21.84M | $-22.99M | $-7.33M |
| Low Forecast | $-21.26M | $-21.41M | $-19.60M | $-19.76M | $-18.21M | $-19.40M | $-20.61M | $-20.31M | $-18.08M | $-25.07M | $-28.00M | $-25.43M | $-19.88M | $-28.73M | $-24.20M | $-25.70M | $-24.20M | $-26.41M | $-18.54M | $-22.54M | $-21.84M | $-22.99M | $-11.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.84% | 1.26% | 0.68% | 1.00% | 0.70% | 0.77% | 0.61% | 1.07% | 0.00% | 0.67% | 0.54% | 1.43% |
RAPT Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RAPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
RAPT Therapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $4.98M | $5.08M | $5.44M | $4.75M | $4.49M | $3.77M | $3.76M | $4.01M | $3.48M | $3.20M | $2.80M | $3.29M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | $582.83K | $1.48M | $1.23M | $1.03M | $3.57M | $3.42M | $4.45M | $3.99M | $5.61M | $4.40M | $3.67M | $5.50M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | $582.83K | $1.48M | $1.23M | $1.03M | $3.57M | $3.42M | $4.45M | $3.99M | $5.61M | $4.40M | $3.67M | $5.50M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | $582.83K | $1.48M | $1.23M | $1.03M | $3.57M | $3.42M | $4.45M | $3.99M | $5.61M | $4.40M | $3.67M | $5.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 8.54% | 3.43% | 4.41% | 4.63% | 1.26% | 1.10% | 0.84% | 1.00% | 0.62% | 0.73% | 0.76% | 0.60% |
RAPT Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to RAPT last annual SG&A of $4.98M (Dec 22).
RAPT Therapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.60 | $-0.62 | $-0.62 | $-0.68 | $-0.61 | $-0.63 | $-0.63 | $-0.66 | $-0.00 | $-0.60 | $-0.51 | $-0.56 |
| Avg Forecast | $-0.55 | $-0.55 | $-0.50 | $-0.51 | $-0.47 | $-0.50 | $-0.53 | $-0.52 | $-0.47 | $-0.56 | $-0.72 | $-0.65 | $-0.67 | $-0.74 | $-0.68 | $-0.66 | $-0.62 | $-0.68 | $-0.60 | $-0.58 | $-0.56 | $-0.59 | $-0.49 |
| High Forecast | $-0.55 | $-0.55 | $-0.50 | $-0.51 | $-0.47 | $-0.50 | $-0.53 | $-0.52 | $-0.47 | $-0.45 | $-0.72 | $-0.65 | $-0.67 | $-0.74 | $-0.68 | $-0.66 | $-0.62 | $-0.68 | $-0.60 | $-0.58 | $-0.56 | $-0.59 | $-0.49 |
| Low Forecast | $-0.55 | $-0.55 | $-0.50 | $-0.51 | $-0.47 | $-0.50 | $-0.53 | $-0.52 | $-0.47 | $-0.65 | $-0.72 | $-0.65 | $-0.67 | $-0.74 | $-0.68 | $-0.66 | $-0.62 | $-0.68 | $-0.60 | $-0.58 | $-0.56 | $-0.59 | $-0.49 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.92% | 0.84% | 1.00% | 0.92% | 1.01% | 0.93% | 1.10% | 0.00% | 1.07% | 0.86% | 1.14% |
According to undefined Wall Street analysts, RAPT Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RAPT previous annual EPS of $NaN (undefined).
RAPT Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RAPT | RAPT Therapeutics | $1.95 | $42.20 | 2064.10% | Hold |
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| XLO | Xilio Therapeutics | $0.82 | $7.00 | 753.66% | Buy |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| HOWL | Werewolf Therapeutics | $2.34 | $12.00 | 412.82% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| PEPG | PepGen | $9.48 | $29.50 | 211.18% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| PHVS | Pharvaris | $20.92 | $38.50 | 84.03% | Buy |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| CNTB | Connect Biopharma | $1.23 | $1.50 | 21.95% | Buy |
| TYRA | Tyra Biosciences | $21.24 | $25.00 | 17.70% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
RAPT Forecast FAQ
Is RAPT Therapeutics a good buy?
No, according to 7 Wall Street analysts, RAPT Therapeutics (RAPT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 42.86% of RAPT's total ratings.
What is RAPT's price target?
RAPT Therapeutics (RAPT) average price target is $42.2 with a range of $27 to $55, implying a 2064.10% from its last price of $1.95. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will RAPT Therapeutics stock go up soon?
According to Wall Street analysts' prediction for RAPT stock, the company can go up by 2064.10% (from the last price of $1.95 to the average price target of $42.2), up by 2720.51% based on the highest stock price target, and up by 1284.62% based on the lowest stock price target.
Can RAPT Therapeutics stock reach $3?
RAPT's average twelve months analyst stock price target of $42.2 supports the claim that RAPT Therapeutics can reach $3 in the near future.
What are RAPT Therapeutics's analysts' financial forecasts?
RAPT Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-78.532M (high $-78.532M, low $-78.532M), average SG&A $0 (high $0, low $0), and average EPS is $-2.021 (high $-2.021, low $-2.021). RAPT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-82.032M (high $-82.032M, low $-82.032M), average SG&A $0 (high $0, low $0), and average EPS is $-2.111 (high $-2.111, low $-2.111).
Did the RAPT's actual financial results beat the analysts' financial forecasts?
Based on RAPT Therapeutics's last annual report (Dec 2022), the company's revenue was $1.53M, beating the average analysts forecast of $982.4K by 55.44%. Apple's EBITDA was $-85.795M, beating the average prediction of $-36.356M by 135.99%. The company's net income was $-81.881M, missing the average estimation of $-90.897M by -9.92%. Apple's SG&A was $20.24M, beating the average forecast of $4.32M by 368.38%. Lastly, the company's EPS was $-2.52, missing the average prediction of $-2.743 by -8.14%. In terms of the last quarterly report (Dec 2022), RAPT Therapeutics's revenue was $641K, beating the average analysts' forecast of $132.5K by 383.77%. The company's EBITDA was $-24.431M, beating the average prediction of $-26.499K by 92095.93%. RAPT Therapeutics's net income was $-21.471M, missing the average estimation of $-25.429M by -15.56%. The company's SG&A was $4.98M, beating the average forecast of $582.83K by 753.94%. Lastly, the company's EPS was $-0.6, missing the average prediction of $-0.654 by -8.29%